BioVersys Advances BV500 NTM Program with CF AMR Syndicate Support

BioVersys AG has announced a significant advancement in its BV500 NTM program. The initiative has reached its second milestone by advancing multiple potent oral Lead candidates. These candidates exhibit broad-spectrum efficacy against non-tuberculous mycobacteria (NTM) in both in vitro and in vivo settings. The program is bolstered by support from LifeArc through the CF AMR Syndicate Collaborative Discovery Programme.

BioVersys leverages its proprietary Ansamycin Chemistry platform to develop BV500 molecules aimed at overcoming resistance. This is particularly crucial for cystic fibrosis patients battling difficult-to-treat NTM lung disease. Collaborative partners in this endeavor include LifeArc, Medicines Discovery Catapult, and the Cystic Fibrosis Trust, who contribute a wealth of expertise to address this medical challenge.

NTM infections, primarily affecting those with preexisting conditions, pose significant treatment challenges. The progress in the BV500 program is a promising step towards providing new therapeutic options for these patients.